New First-Line Treatment for CLL ApprovedDa Hee HanPharmD
This publication highlights expert perspectives on the current therapeutic landscape in chronic lymphocytic leukemia with emphasis on factors affecting treatment selection including novel regimens, combination therapies, and ongoing clinical trials.EP: 1.Dr. Ma on Utilizing Zanabrutinib in CLL EP: 2.Dr....
we make sure to diagnose them well. We do flow cytometry, and we do everything that is required to come up with the CLL diagnosis. However, they’re not going to need treatment right away. Treatment is really reserved for those patients who have aggressive disease...
This review will discuss the cellular responses controlled by p53 that contribute to tumour suppression, p53 mutant lung cancer mouse models and characterisation of p53 mutant lung cancer. Furthermore, we discuss potential approaches of targeting mutant p53 for the treatment of lung cancer....
et al. Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. Cancer Discov. 3, 1302–1315 (2013). CAS PubMed Google Scholar Landen, C. N. Jr et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 65, 6910...
②The New England Journal of Medicine:Trial of Selective Early Treatment of Patent Ductus Arteriosus with Ibuprofen 通过一项多中心、随机、双首、安慰剂对照试验研究受布洛芬用于早产儿动脉导管未闭(PDA)的影响 DOI: 10.1056/NEJMoa2305582 ③The New England Journal of Medicine:Wearable Digital Health Technolog...
Chimeric antigen receptor (CAR) T-cell therapy represents a highly efficacious treatment modality demonstrated to enhance outcomes in patients afflicted with malignancies, particularly those enduring relapsed or refractory hematological malignancies. How
During the 2020 ASCO Virtual Scientific Program, findings from several studies evaluating immunotherapy as monotherapy and in combination strategies were presented, highlighting the evolving treatment landscape for patients with non–small cell lung cancer (NSCLC), explained David R. Spigel, MD. Recently...
“汉利康®has shown good efficacy and reliable safety in clinical studies. As the first rituximab approved in China for the treatment of rheumatoid arthritis, 汉利康®will effectively boost patients' confidence in continuous medication with low-frequency administration and sustained efficacy and make ...
There have been major advances in the immunotherapy of cancer in recent years, including the development of T cell engagers — antibodies engineered to redirect T cells to recognize and kill cancer cells — for the treatment of haematological malignancies. However, the field still faces several chal...